|
|
Volumn 113, Issue 24, 2009, Pages 6258-
|
|
On the malignant potential of thiopurine therapy
a
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;
MERCAPTOPURINE;
METHOTREXATE;
ANTINEOPLASTIC AGENT;
METHYLTRANSFERASE;
THIOPURINE METHYLTRANSFERASE;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE LYMPHOBLASTIC LEUKEMIA;
APOPTOSIS;
CHILDHOOD LEUKEMIA;
GENE FREQUENCY;
GENE MUTATION;
HEMATOLOGIC MALIGNANCY;
HUMAN;
LETTER;
MYELODYSPLASTIC SYNDROME;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SECOND CANCER;
TREATMENT DURATION;
CHEMICALLY INDUCED DISORDER;
DRUG EFFECT;
ENZYME IMMUNOASSAY;
GENETICS;
KARYOTYPING;
METABOLISM;
MULTIMODALITY CANCER THERAPY;
MUTATION;
NOTE;
ORAL DRUG ADMINISTRATION;
PATHOLOGY;
PROGNOSIS;
REMISSION;
RISK FACTOR;
SKULL IRRADIATION;
STEM CELL TRANSPLANTATION;
SURVIVAL RATE;
TREATMENT OUTCOME;
6-MERCAPTOPURINE;
ADMINISTRATION, ORAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COMBINED MODALITY THERAPY;
CRANIAL IRRADIATION;
HUMANS;
HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;
IMMUNOENZYME TECHNIQUES;
KARYOTYPING;
METHOTREXATE;
METHYLTRANSFERASES;
MUTATION;
NEOPLASMS, SECOND PRIMARY;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
PROGNOSIS;
REMISSION INDUCTION;
RISK FACTORS;
STEM CELL TRANSPLANTATION;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 67650346178
PISSN: 00064971
EISSN: 15280020
Source Type: Journal
DOI: 10.1182/blood-2009-03-208413 Document Type: Letter |
|
Times cited : (3)
|
|
References (4)
|
